Arvelle   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Fair Lawn NJ United States (1993)
Status: Acquired by Angelini (2021)

Organization Overview

First Clinical Trial
2002
NCT00109083
First Marketed Drug
2019
cenobamate (Xcopri)
First NDA Approval
2019
cenobamate (Xcopri)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SK LIFE | SK Life Science | SK Life Science, Inc. | SK LIFE SCIENCE INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constipation (Phase 2)

Diabetic Neuropathies (Phase 2)

Drug Resistant Epilepsy (Phase 2)

Epilepsies, Partial (Phase 3)

Epilepsy (Phase 3)

Epilepsy, Complex Partial (Phase 3)

Epilepsy, Generalized (Phase 3)

Epilepsy, Partial, Motor (Phase 3)

Essential Tremor (Phase 2)

Headache (Phase 2)

Herpes Zoster (Phase 2)

Lennox Gastaut Syndrome (Phase 1)

Migraine Disorders (Phase 2)

Mononeuropathies (Phase 2)

Movement Disorders (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Polyneuropathies (Phase 2)

Schizophrenia (Phase 2)

Seizures (Phase 3)

Syndrome (Phase 1)

Tremor (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 41
  • # of Trial APIs: 15